The Russian Direct Investment Fund (RDIF) has recently announced that the country would supply 25 million doses of the Sputnik V coronavirus vaccine to Nepal via Trinity Pharmaceuticals.
The human adenovirus-based vaccine candidate is currently undergoing phase 3 trials, and its distribution in Nepal is subject to approval by the nation’s government upon successful completion of the study, according to Kishor Adhikari, Director of Trinity Pharmaceuticals.
The agreement will enable 90% of the population of Nepal to get access to Sputnik V vaccine and provide country’s clinics with an anti-COVID vaccine with proven safety and efficacy, said RDIF.
The Sputnik V vaccine was developed by the Gamaleya National Research Institute of Epidemiology and Microbiology on August 11, and approved by the Russian Ministry of Health to become the world’s first registered vaccine against COVID-19 based on the human adenoviral vectors platform.
Sputnik V is a viral two-vector vaccine based on the human adenovirus or the common cold virus that is fused with the spike protein of SARS-CoV-2 to stimulate an immune response. The recombinant adenovirus type-5 (Ad5) and adenovirus type-26 (Ad26) were both used as vectors in the vaccine. The Ad26 based vaccine is recommended to be used initially and the Ad5 vaccine has to be used on the 21st day to boost response.
Just over a month of launching Russia’s ‘Sputnik V’ vaccine against the novel coronavirus, the Russian government said that over 3,000 Moscow residents have got the dose of its first COVID-19 vaccine till now, according to a report.
However, the vaccine has been tested only in a small number of people in early-stage clinical trials that lasted two months, which is unlike a standard clinical trial that took a year or more of clinical assessment for proof of vaccine safety and efficacy against the disease.
The studies from phase 1 and phase 2 of the vaccine candidate concluded to be safe and to have produced immune response even though the trial was only conducted in 76 participants. The findings are published in the journal The Lancet.
More than 50 countries in Asia, Middle East, Latin America, Europe and CIS have applied for Sputnik V. RDIF has announced earlier supply agreements with Mexico for 32 million doses, with Brazil for up to 50 million doses, India – 100 million doses and Uzbekistan – for up to 35 million doses.